for the six months ended 31 December 2021 -- 1 of 50 -- NORMALISED PROFIT FROM OPERATIONS (R million) 2017 2018 2019 2020 2021 4 507 3 792 3 799 3 941 4 872 GROSS INFLOWS UNDER MANAGEMENT (R million) 2017 2018 2019 2020 2021 79 683 74 774 67 541 60 655 85 664 EMBEDDED VALUE (R million) 2017 2018 2019 2020 2021 72 467 73 184 68 025 60 408 82 920 CORE NEW BUSINESS API (R million) 2017 2018 2019 2020 2021 9 916 9 584 9 066 7 814 10 475 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 2 of 50 -- 1 COMMENTARY STRONG OPERATING PERFORMANCE AND RESILIENCE DURING THE PANDEMIC AND A DRIVE FOR GROWTH MANIFESTING IN THIS PERIOD THROUGH STRONG PERFORMANCE BY DISCOVERY BANK AND THE ESTABLISHMENT OF AMPLIFY HEALTH The complexity in the operating environment continued over the six months ended 31 December 2021, which included the COVID-19 Delta and Omicron variants, as well as significant market volatility due to movements in exchange rates and interest rates in South Africa (“SA”) and the United Kingdom (“UK”). Against this backdrop, the strategic focus of the Group over the period remained three-pronged: 1) Navigating the significant impact of the COVID-19 pandemic to maintain robust financial performance; 2) Building on the relevance of the business model by driving for growth, with excellent traction in Discovery Bank and the conclusion of the Amplify Health transaction with AIA Group Limited (“AIA”), announced on 15 February 2022; and 3) Ensuring financial resilience through disciplined cash and capital management. RESILIENT OPERATING PERFORMANCE For the six months ended 31 December 2021 (“the reporting period, current period or this period”), normalised operating profit increased by 8% to R4 872 million and normalised headline earnings increased by 26% to R2 876 million. Core new business annualised premium income (API) was up 6% to R10 475 million, as new business trends in SA and the UK improved over the period while persistency has continued to exceed expectations. Investment in new initiatives impacting normalised operating profit was at 17%1 of earnings for the six months ended 31 December 2021, compared with 18% (in the previous period), with Discovery Bank constituting half of the investment. Normalised headline earnings per share (basic) increased by 26% to 437.7 cents and headline earnings per share (basic) increased by 78% to 499.1 cents. Normalised headline earnings were positively impacted by mark-to-market foreign currency gains arising from a weakening of the rand during the reporting period compared with losses due to the rand strengthening in the previous period. This gain was partly offset by substantial support provided to the national mass vaccination campaign in SA, for which Discovery spent R137 million over the reporting period. Headline earnings further improved as a significant reduction in real interest rates in SA resulted in positive economic basis changes recognised in the income statement, compared with negative economic basis changes in the prior period. In addition, the rand depreciation, as explained above, had a further positive impact on reported growth in headline earnings. Discovery generated a strong return on opening embedded value (RoEV) of 22.7% annualised, or 14% excluding the impact of COVID-19, forex, and economic changes. Strong lapse experience remains a key feature across all operations. 1. As a percentage of established and emerging normalised profit from operations. The following table highlights key items: Normalised profit from operations, current period, in ZAR million % change (Current period vs prior period) Core new business API, current period in ZAR million % change (Current period vs prior period Discovery Health 1 750 5 3 598 29 Discovery Life 1 934 1 1 267 9 Discovery Invest 517 10 1 519 15 VitalityHealth 850 39 708 11 VitalityLife 361 10 554 (1) Discovery Insure 15 (86) 597 (3) Vitality Group 234 (2) Ping An Health Insurance (25% interest) 140 25 1 426 (21) Discovery Bank (498) 18 (reduction in spend) Other new initiatives (Excluding Bank) 1 (470) 21 (increase in spend) 772 (23) Core new business API2 10 475 6 Normalised profit from operations 2 4 872 8 Normalised headline earnings 2 876 26 Headline earnings 3 278 78 1. Refer to normalised profit from operations regional disclosure for regional composition of new initiative spend; Core API for other new initiatives includes Umbrella Fund, Discovery Insure commercial and VitalityInvest – new business was impacted by the lumpy nature of Umbrella Fund sales which had strong growth in the prior period. 2. Includes SA Vitality: normalised profit from operations includes R39 million (prior period: R46 million); core new business API includes R34 million (prior period: R24 million). 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 25 FEbRUARY 2022 -- 3 of 50 -- 2 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 COMMENTARY continued ONGOING RESPONSE AND RESILIENCE TO THE COVID-19 PANDEMIC: PROVISIONS ADEQUATE The Group has navigated the COVID-19 pandemic across its global operations, with mortality risk in SA having the largest impact financially. The reporting period included the end of the Delta variant third wave of the COVID-19 pandemic in SA, in the latter part of September 2021, and the start of the highly infectious Omicron variant resulting in a fourth wave in SA commencing towards the end of November 2021. During the current period, the third wave led to a significant number of deaths in SA while the fourth wave has seen a considerable increase in the number of new infections, but with less severe clinical outcomes compared with the other waves of infections. Discovery continued to support SA in its mass vaccination roll-out across its vaccination sites. There was careful financial management of the Group during this period. While R3.4 billion in COVID-19 claims, gross of reinsurance, were paid by Discovery Life (DL) in the reporting period (the highest throughout the pandemic), the earnings impact was limited given its strong reinsurance arrangements and previously raised provisions proving adequate. The Group believes the remaining provisions are sufficient to withstand a potential fifth wave. This is supported by high levels of vaccination among its clients and high levels of immunity in SA, borne out by the significant reduction in case fatality rates from Omicron in the fourth wave. Liquidity and solvency remained strong across the Group and the financial leverage ratio improved to 23.9%2, well below the internally set guidance threshold of 28%. In all markets, the Group has looked to add value to its customers and to the communities in which it operates. In SA, aside from playing an active role in driving vaccination take-up as mentioned, Discovery Health (DH) contributed to the global research agenda with its COVID-19 analysis and research, releasing an at-scale, real-world analysis of the Omicron outbreak in December 2021 to analyse vaccine effectiveness. DRIVE FOR GROWTH, WITH EXCELLENT TRACTION IN DISCOVERY bANK AND CONCLUSION OF AMPLIFY HEALTH The Group continued to see the relevance and impact of its business model given the acceleration and deepening of global trends. These include ongoing opportunities to incentivise consumers due to the behavioural nature of risk; the acceleration of digital transformation and rise of personalisation as new standards for success; as well as the Environmental, Social and Governance imperative as business shifts to provide value for all stakeholders. The uniqueness and sophistication of the Vitality Shared-value Insurance model has led to a powerful platform of integrated assets and capabilities, well-positioned to respond to this macro context. The model has proven its relevance in each business and organically, the Group has developed significant scale and foundations for growth in each market. In this period, the relevance of the business model was demonstrated in two specific areas and opportunities: Discovery Bank’s performance exceeded expectation, with excellent performance across all metrics and advanced its strategic objective of forming the basis of the SA composite. In addition, Discovery is injecting its Vitality and Health capabilities into a new health InsurTech Joint Venture with the AIA Group in Asia, called Amplify Health – a powerful endorsement of the platform that has been built and opportunity for further expansion and growth. Amplify Health is an important manifestation of globalising Discovery’s wellness and health capabilities, extending the very successful partnership between Discovery and AIA. This positions the Group for growth across fast-expanding Asian healthcare markets, covering China through Ping An Health Insurance and the remaining Pan- Asian markets through Amplify Health. The period also saw further progress made in the market-specific strategies and strategic objectives of the Group: i. South Africa: To be the perfect composite model, number 1 in every industry, and the Bank pivoting to growth as the composite- maker within SA ii. United Kingdom: To have best-in-breed products across businesses and operating as a fully integrated composite business with a seamless One Vitality client journey and to have a successful entry into motor insurance iii. Vitality Global (incorporating Vitality Group and Ping An Health Insurance): To be the leading wellness and healthcare platform that provides preeminent life and health insurers globally with our Vitality Shared Value and health management capabilities to assist them in making their customers healthier, while ensuring their products are more competitive with better margins This resulted in strong operating profit in these respective strands and significant investment in offshore expansion. 2. Excludes capitalised lease liabilities under IFRS16 Leases and bank borrowings related to normal course lending and borrowing activities. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 4 of 50 -- 3 DH delivered a resilient financial performance, supported by continued operational efficiency and new business over the period. Normalised operating profit increased by 5% to R1 750 million, while gross income increased by 4% to R4 477 million for H1 FY22. Total new business API increased by 14% to R3 598 million (core new business API, which excludes the new closed scheme added in the prior period, increased by 29%). In addition to the Discovery Health Medical Scheme (DHMS), DH administers 18 closed medical schemes, all of which showed excellent performance across the board, with contribution increases materially lower than medical inflation, and the majority demonstrating improving solvency levels. DH has continued to grow non-medical scheme products (FlexiCare, Gap Cover and Healthy Company), showing 28% growth in this period with c.238 000 non-medical scheme lives now under DH’s administration. Total non-medical scheme revenue exceeded R550 million and now represents 13% of the total DH revenue. DHMS has continued to perform strongly: new business levels showed signs of post-COVID-19 recovery and the Scheme showed net growth of 17 835 lives for the six months, while lapse rates remained below pre-COVID-19 levels. Consequently, DHMS’s share of the open medical scheme market has grown to 57.5% by the end of Q3 2021. DHMS provided financial relief for its members through the deferred implementation of both the 2021 and 2022 DHMS contribution increases. This deferral has protected DHMS members in real terms, cumulatively saving members approximately R2 billion during 2021, while concurrently ensuring that DHMS is correctly priced for forecast medical inflation. DHMS capital reserves have increased to an unaudited solvency level of 38%, pursuant to the reduction in non-COVID-19 healthcare utilisation, assuring members of robust financial strength. Discovery Health BUSINESS-SPECIFIC PERFORMANCE South Africa FINANCIAL PERFORMANCE The SA composite’s normalised operating profit increased by 4% to R3 582 million. Discovery Bank constitutes the largest investment into new initiatives, with Discovery Business Insurance (DBI) and Umbrella Funds (UF) being much less material, given the progress made. Discovery Bank’s normalised operating loss for the period under review was better than planned at R498 million, 18% lower than the prior period. The Bank continued to gain traction with 385 200 clients (versus 287 182 clients in December 2020) and 793 215 accounts (versus 540 252 accounts in December 2020), expanding its existing Discovery and non-Discovery client base and achieving more than 750 average daily new-to-Bank sales in January, higher than the current plan. Retail deposits grew by 69% to R9.5 billion and advances grew at 10% to R4.1 billion at 31 December 2021. Customer quality remains excellent with high average levels of non-interest revenue per client and the quality focused credit strategy was evidenced by the low credit loss ratio of 0.96%. The benefits of the business model continue to manifest in improving operating leverage, with overall costs remaining constant in real terms, notwithstanding the significant customer growth and product innovations. Discovery Bank 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 5 of 50 -- 4 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 COMMENTARY continued Discovery Invest grew normalised operating profit by 10% to R517 million, while fee income grew by 24% (to R1 388 million). Normalised operating profit growth was impacted by a once-off guaranteed inflation linked matching portfolio profit in the prior period of R44 million. New business increased 15% to R1 519 million, despite a 14% drop in sales of guaranteed plans as a result of lower guaranteed rates following the depletion of the tax asset. Total Assets under Administration grew by 19% to R128 billion, with Assets under Management increasing by 23% to R84.7 billion. Linked funds placed in Discovery funds remain high at 79.8%. Net inflows amounted to R3.1 billion, an 11% increase from the prior year. Discovery Invest Discovery Insure had a difficult period, with normalised operating profit falling 86% to R15 million. The increased loss ratio was driven by adverse weather events combined with motor parts inflation dramatically exceeding CPI as well as elevated power surge and fire claims. New business API declined 3%, with the prior period delivering a particularly strong result, however gross written premium remained resilient, increasing by 13% to R 2 318 million for the personal lines business, with Discovery Insure maintaining an estimated 7% of the personal lines market share. Discovery Insure DL’s normalised operating profit increased 1% to R1 934 million, driven by the positive overall experience and strong lapse experience in particular. The COVID-19 claims experience was consistent with provision modelling. The earnings growth must be seen in the context of Discovery Life having paid out cumulatively R6.4 billion in COVID-19 claims, gross of reinsurance, since the start of the pandemic (R3.4 billion in the current period), with returns on the reduced asset base impacting earnings by c.13%. DL also benefitted from a R498 million positive economic impact due to economic assumptions, but this is excluded from normalised operating profit. New business increased by 9% to R1 267 million, driven by strong Automatic Contribution Increases with the DL new business margin increasing to 6.8%, which contributed to a 15% RoEV (including Discovery Invest), before the inclusion of gains from the economic assumptions impact. DL’s financial position remains robust with a solvency ratio of 184% and strong liquidity buffers remaining intact under all modelled COVID-19 scenarios. Provisions within the individual life book were sufficient for the claims incurred in the reporting period and the Group believes that remaining provisions of R502 million (including Discovery Invest), net of reinsurance, are sufficient to withstand a potential fifth wave. This is supported by high levels of vaccination among its clients and high levels of immunity due to previous infections in SA, borne out by the significant reduction in case fatality rates in the fourth wave. Discovery Life 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 6 of 50 -- 5 VitalityLife’s (VL) normalised operating profit grew by 15% to £17.6 million (R361 million, up 10%), driven by strong operating variances over the period. Despite a challenging sales environment, new business API increased by 3% to £27.1 million (down 1% to R554 million). The hedge structure continues to negate the impact of interest rate movements; regular rebalancing was required given high levels of interest rate volatility in the period, resulting in rebalancing costs of £2.2 million incurred over the period. The continued strong retention performance delivered 7% higher earned premiums, to £164 million (up 3% to R3 359 million), while lives covered grew by 6% year-on-year, exceeding c. 686 000. VL maintained a £2.87m (R62 million) COVID-19 provision at 31 December 2021 because of remaining uncertainty. Prudential and Discovery have made significant progress in agreeing the terms of a long-term deferral of the Part VII transfer of the VitalityLife book currently written on the Prudential balance sheet to Vitality Life Limited, such that a Part VII transfer would not be required by May 2023 as per the current agreement. The new agreement is currently expected to be completed by 30 June 2022 and would be reflected in the Discovery embedded value and Group funding plan at that point. VitalityLife (VL) VitalityHealth’s (VH) normalised operating profit grew by 44% year-on-year to £41.5 million (up 39% to R850 million). The incidence of claims has returned to pre-COVID-19 levels, although the severity and cost of claims were still less than expected. As uncertainty around claims persists, the Unearned Premium Reserve (UPR) adjustment at 31 December 2021 remains largely in line with June levels. There was a strong sales performance over the period with new business API increasing 15% year-on-year to £34.5 million (up 11% to R708 million), through good progress in the direct channels. Excellent retention was maintained and earned premiums grew by 7% to £274.0 million (R5 606 million, up 3%), excluding the UPR adjustment, and total lives grew 10% to c.764 000. Cash generation was robust over the period, with the back book generating £67.8 million (R1 389 million) in cash. After new business acquisition costs and investment in developing the business, VH generated a £30.7 million (R629 million) cash surplus. VitalityHealth United Kingdom The UK composite‘s normalised operating profit increased by 36% to £54.2 million (R1 110 million, up 30%). Earned premiums increased by 7% year-on-year to £438.0 million (R8 965 million, up 3%), excluding the Unearned Premium Reserve adjustment. The UK has invested 8% of profits into new initiatives, predominantly VitalityInvest (VI), which at 31 December 2021 had almost doubled its total funds under management compared with 12 months prior to £659.6 million (R14.1 billion). Ping An Health’s (PAH) profit from operations, represented by the Group’s share of after-tax operating profit less the costs to support the business, grew by 25% to R140 million. Total written premium grew by 13% to R20.4 billion (RMB8.7 billion), achieving a c.8.5% market share. New business API reduced 21% to R5.7 billion (RMB2.4 billion), primarily due to a restructuring of the cooperation with Ping An Life for business written in certain regions in China. This is part of the overall re-alignment of PAH to focus on growing high quality own license business, given its increased scale and maturing business model. These changes are not expected to impact growth in profitability going forward. PAH is ranked as the 16th most profitable among all life and health insurers in China3 and profit growth continued to outperform the market, through improved lapse experience, prudent expense management and investments in underwriting and claims management. Ping An Health Insurance 3. Chinese Life Insurers Ranking Q3 2021. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 7 of 50 -- 6 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 COMMENTARY continued GROWTH PROSPECTS AND DIVIDEND Discovery’s business model has proven to be highly relevant during the COVID-19 pandemic, with robust underlying growth trends developing in most parts of the business. The Group is capitalising on its growth opportunities while ensuring operational resilience despite the challenging macro environment. The effect of continued interest rate and currency volatility in SA is expected to remain a feature of the reported results. During the period under review, Discovery made a capital contribution to PAH of R1.5 billion as highlighted in the previous reporting period. While this was funded in the interim by way of a bridge facility and internal resources, as explained at the time, Discovery still anticipates raising a specific quantum of equity capital for this purpose in line with the disciplined framework of its capital plan. Despite the Group’s robust capital position, due to the continued uncertainty caused by COVID-19 on the demographic and economic environment in SA, the Discovery Board has decided to retain its prior stated position during the pandemic and has decided not to declare an ordinary interim dividend for the period ended 31 December 2021. The reintroduction of an ordinary dividend will be considered on an ongoing basis. NOTES TO ANALYSTS – Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company's external auditors. – Discovery has published supplemental unaudited information on the website. For this and other results information, go to https://www.discovery.co.za/corporate/investor-relations and page down to Financial results and statements, 2022. On behalf of the Board ME Tucker Chairperson A Gore Group Chief Executive Sandton 23 February 2022 Vitality Group’s (VG) profit increased by 7% to US$15.5 million as a consequence of foreign exchange realised gains in the prior period not being repeated. In rand value, the profit decreased by 2% to R234 million due to the strengthening of the average exchange rates over the period. VG has increased its investment into Vitality Health International (VHI), leading to an expanding global reach with large upside potential – the period included the announcement of the Amplify Health transaction. Revenue growth remained resilient, with fee income growing 16% to US$44.5 million (R668 million) and insurance partners’ Vitality-integrated premiums growing by 37% to US$766 million (R11.5 billion). Sales growth in AIA markets is still being adversely impacted by COVID-19 but has recovered somewhat, while Sumitomo Life Vitality is close to reaching a milestone of 1 million Vitality-linked policies sold since launching in 2018. Generali Vitality Czech Republic is expected to launch in March 2022 and Generali Vitality Poland in May 2022. The period also saw Vitality expand to 36 markets (including SA and the UK). Vitality membership from insurance partners grew 33% to 2.7 million. Vitality Group 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 8 of 50 -- 7 STATEMENT OF FINANCIAL POSITION at 31 December 2021 R million GROUP DECEMBER 2021 UNAUDITED Group June 2021 Audited Assets Goodwill 5 098 4 879 Intangible assets 6 607 6 371 Property and equipment 4 044 4 188 Assets arising from insurance contracts 56 578 50 483 Deferred acquisition costs 599 585 Assets arising from contracts with customers 1 390 1 248 Investment in equity-accounted investments 5 609 3 459 Deferred income tax 3 917 3 948 Financial assets – Loans and advances to customers at amortised cost 3 610 3 361 – Investments at amortised cost 6 799 5 604 – Investments at fair value through profit or loss 146 524 130 937 – Derivative financial instruments at fair value through profit or loss 294 249 Insurance receivables, contract receivables and other non-financial receivables 12 558 10 533 Current income tax asset 485 391 Reinsurance contracts 522 445 Cash and cash equivalents 19 756 20 013 TOTAL ASSETS 274 390 246 694 Equity Capital and reserves Ordinary share capital and share premium 10 163 10 151 Perpetual preference share capital 779 779 Other reserves 4 402 1 935 Retained earnings 36 827 33 550 Equity attributable to owners of the Company 52 171 46 415 Non-controlling interest 4 4 TOTAL EQUITY 52 175 46 419 Liabilities Liabilities arising from insurance contracts 112 740 100 977 Liabilities arising from reinsurance contracts 14 189 12 525 Deferred income tax liability 9 509 8 814 Contract liabilities to customers 721 776 Financial liabilities – Borrowings at amortised cost 19 804 19 493 – Other payables at amortised cost 15 289 14 904 – Deposits from customers at amortised cost 10 356 8 985 – Investment contracts at fair value through profit or loss 38 347 32 291 – Derivative financial instruments at fair value through profit or loss 667 826 Employee benefits 299 315 Current income tax liability 294 369 TOTAL LIABILITIES 222 215 200 275 TOTAL EQUITY AND LIABILITIES 274 390 246 694 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 9 of 50 -- 8 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 INCOME STATEMENT for the six months ended 31 December 2021 R million GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited % change Group Year ended June 2021 Audited Insurance premium revenue 29 218 26 539 55 935 Reinsurance premiums (3 906) (3 818) (7 729) Accelerated reinsurance premiums – – (823) Net insurance premium revenue 25 312 22 721 11 47 383 Fee income from administration businesses 6 180 5 695 11 700 Vitality income 1 739 1 743 3 340 Net banking fee and commission income 280 219 28 480 Banking fee and commission income 391 296 633 Banking fee and commission expense (111) (77) (153) Net bank interest and similar income 138 137 1 241 Bank interest and similar income using the effective interest rate 377 302 627 Bank interest and similar expense using the effective interest rate (239) (165) (386) Investment income using the effective interest rate method 145 150 280 Net fair value gains on financial assets at fair value through profit or loss 8 330 5 513 11 891 Other income 610 499 1 372 Receipts arising from reinsurance contracts – 500 500 Net income 42 734 37 177 15 77 187 Net claims and policyholders’ benefits (15 944) (13 147) (21) (28 178) Claims and policyholders’ benefits (20 283) (15 604) (33 972) Insurance claims recovered from reinsurers 4 339 2 457 5 794 Acquisition costs (3 061) (2 883) (5 033) Marketing and administration expenses (12 047) (10 824) (22 679) Amortisation of intangibles from business combinations (30) (35) (66) Expected credit losses (19) (228) (271) Recovery of expenses from reinsurers 1 237 1 317 2 773 Net transfer to/from assets and liabilities under insurance contracts (6 078) (6 534) (14 795) – change in assets arising from insurance contracts 4 119 2 858 545 – change in assets arising from reinsurance contracts 57 87 56 – change in liabilities arising from insurance contracts (9 780) (8 166) (17 941) – change in liabilities arising from reinsurance contracts (996) (1 138) 1 755 – economic assumption adjustments net of discretionary margins 522 (175) 790 Fair value adjustment to liabilities under investment contracts (1 576) (1 207) (3 634) Profit from operations 5 216 3 636 43 5 304 Finance costs (834) (826) (1 648) Foreign exchange gains/(losses) 128 (362) (389) Gain on dilution and disposal of equity-accounted investments 4 – 554 Impairment of equity-accounted investments – – (149) Share of net profits from equity-accounted investments 207 155 523 Profit before tax 4 721 2 603 81 4 195 Income tax expense (1 416) (728) 95 (975) Profit for the period 3 305 1 875 76 3 220 Profit attributable to: – ordinary shareholders 3 277 1 841 3 157 – preference shareholders 28 34 63 – non-controlling interest * * * 3 305 1 875 76 3 220 Earnings per share for profit attributable to ordinary shareholders of the company during the year (cents): – basic 498.8 280.2 78 480.7 – diluted 492.5 277.8 77 475.4 * Amount is less than R500 000. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 10 of 50 -- 9 STATEMENT OF OTHER COMPREHENSIVE INCOME for the six months ended 31 December 2021 R million GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited % change Group Year ended June 2021 Audited Profit for the period 3 305 1 875 76 3 220 Items that are or may be reclassified subsequently to profit or loss: Currency translation differences 1 729 (1 306) (1 576) Cash flow hedges 117 77 260 – unrealised gains 146 276 360 – tax on unrealised gains (5) (55) (25) – gains recycled to profit or loss (26) (180) (90) – tax on recycled gains 2 36 15 Share of other comprehensive income from equity-accounted investments 470 (153) (312) – change in fair value of debt instruments at fair value through other comprehensive income 18 7 15 – currency translation differences 452 (160) (327) Other comprehensive income/(losses) for the period, net of tax 2 316 (1 382) (268) (1 628) Total comprehensive income for the period 5 621 493 1 040 1 592 Attributable to: – ordinary shareholders 5 593 459 1 119 1 529 – preference shareholders 28 34 63 – non-controlling interest * * * Total comprehensive income for the period 5 621 493 1 040 1 592 * Amount is less than R500 000. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 11 of 50 -- 10 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 11 STATEMENT OF CHANGES IN EQUITY at 31 December 2021 Attributable to equity holders of the Company Attributable to equity holders of the Company R million SHARE CAPITAL AND SHARE PREMIUM PREFERENCE SHARE CAPITAL SHARE- BASED PAYMENT RESERVE INVESTMENT RESERVE1 FOREIGN CURRENCY TRANSLATION RESERVE HEDGING RESERVE RETAINED EARNINGS TOTAL NON- CONTROLLING INTEREST TOTAL Period ended 31 December 2021 At beginning of the period 10 151 779 489 18 1 772 (344) 33 550 46 415 4 46 419 Total comprehensive income for the period – 28 – 18 2 181 117 3 277 5 621 * 5 621 Profit for the period – 28 – – – – 3 277 3 305 * 3 305 Other comprehensive income – – – 18 2 181 117 – 2 316 – 2 316 Transactions with owners 12 (28) 151 – – – – 135 – 135 Share issue 443 – – – – – – 443 – 443 Increase in treasury shares (443) – – – – – – (443) – (443) Delivery of treasury shares 12 – (12) – – – – – – – Employee share option schemes: – Value of employee services – – 163 – – – – 163 – 163 Dividends paid to preference shareholders – (28) – – – – – (28) – (28) At end of the period 10 163 779 640 36 3 953 (227) 36 827 52 171 4 52 175 Period ended 31 December 2020 At beginning of the period 10 148 779 195 3 3 675 (604) 30 353 44 549 4 44 553 Total comprehensive income for the period – 34 – 7 (1 466) 77 1 841 493 * 493 Profit for the period – 34 – – – – 1 841 1 875 * 1 875 Other comprehensive income – – – 7 (1 466) 77 – (1 382) – (1 382) Transactions with owners 12 (34) 111 – – – – 89 – 89 Share issue 907 – – – – – – 907 – 907 Increase in treasury shares (907) – – – – – – (907) – (907) Delivery of treasury shares 12 – (10) – – – – 2 – 2 Employee share option schemes: – Value of employee services – – 121 – – – – 121 – 121 Dividends paid to preference shareholders – (34) – – – – – (34) – (34) At end of the period 10 160 779 306 10 2 209 (527) 32 194 45 131 4 45 135 1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments. * Amount is less than R500 000. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 12 of 50 -- 12 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 STATEMENT OF CASH FLOWS for the six months ended 31 December 2021 R million GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited Group Year ended June 2021 Audited Net cash flow from operating activities 2 185 6 612 10 407 Cash generated by operations 8 554 7 247 19 485 Purchase of investments held to back policyholder liabilities (42 395) (24 105) (54 661) Proceeds from disposal of investments held to back policyholder liabilities 36 138 19 335 38 709 Working capital changes (66) 4 667 6 972 Cash generated from operating activities 2 231 7 144 10 505 Dividends received 482 59 303 Interest received 1 057 1 012 2 513 Interest paid (786) (606) (1 197) Taxation paid (799) (997) (1 717) Net cash flow from investing activities (3 420) (3 599) (6 740) Purchase of financial assets (16 065) (15 658) (32 569) Proceeds from disposal of financial assets 14 968 13 136 27 828 Purchase of property and equipment (122) (136) (277) Proceeds from disposal of property and equipment 13 3 21 Purchase of software and other intangible assets (743) (771) (1 587) Acquistion of business net of cash – (25) (25) Additional investment in equity-accounted investments (1 525) (148) (240) Dividends from equity-accounted investments 54 – 109 Net cash flow from financing activities (127) 595 (590) Dividends paid to preference shareholders (28) (34) (63) Proceeds from borrowings 1 548 919 1 839 Repayment of borrowings (1 647) (290) (2 366) Net (decrease)/increase in cash and cash equivalents (1 362) 3 608 3 077 Cash and cash equivalents at beginning of the period 20 013 17 909 17 909 Exchange gains/(losses) on cash and cash equivalents 1 105 (780) (973) Cash and cash equivalents at end of the period 19 756 20 737 20 013 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 13 of 50 -- 13 ADDITIONAL DISCLOSURE for the six months ended 31 December 2021 FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three levels that reflect the significance of the inputs used in measuring fair value. These are as follows: Level 1 includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's length basis. Level 2 includes financial instruments that are valued using techniques based significantly on observable market data. Instruments in this category are valued using: (a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or (b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable market data. Level 3 includes financial instruments that are valued using valuation techniques that incorporate information other than observable market data and where at least one input (which could have a significant effect on instruments' valuation) cannot be based on observable market data. R million (unaudited) 31 DECEMBER 2021 LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Financial assets Financial instruments mandatorily at fair value through profit or loss: – Equity portfolios 52 581 3 892 – 56 473 – Debt portfolios 43 648 1 840 – 45 488 – Money market portfolios 6 575 5 534 – 12 109 – Multi-asset portfolios 32 454 – – 32 454 Derivative financial instruments at fair value: – used as cash flow hedges – 43 – 43 – not designated as hedging instruments – 251 – 251 Total financial assets 135 258 11 560 – 146 818 Financial liabilities Investment contracts at fair value through profit or loss – 38 347 – 38 347 Derivative financial instruments at fair value: – used as cash flow hedges – 302 – 302 – not designated as hedging instruments – 365 – 365 Total financial liabilities – 39 014 – 39 014 There were no transfers between level 1 and 2 during the current financial period. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 14 of 50 -- 14 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 ADDITIONAL DISCLOSURE continued for the six months ended 31 December 2021 FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS continued R million (audited) 30 June 2021 Level 1 Level 2 Level 3 Total Financial assets Financial instruments mandatorily at fair value through profit or loss: – Equity portfolios 40 530 2 832 – 43 362 – Debt portfolios 34 845 1 640 – 36 485 – Money market portfolios 6 451 10 802 – 17 253 – Multi-asset portfolios 33 837 – – 33 837 Derivative financial instruments at fair value: – used as cash flow hedges – 28 – 28 – not designated as hedging instruments – 221 – 221 Total financial assets 115 663 15 523 – 131 186 Financial liabilities Investment contracts at fair value through profit and loss – 32 291 – 32 291 Derivative financial instruments at fair value: – used as cash flow hedges – 461 – 461 – not designated as hedging instruments – 365 – 365 Total financial liabilities – 33 117 – 33 117 Specific valuation techniques used to value financial instruments in level 2 ❚ Discovery has invested in equity linked notes offered by international banks in order to back certain unit-linked contract liabilities. The calculation of the daily value of the equity linked investments is made by the provider of the note. Discovery has procedures in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds and movement since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed to the policyholders, which is recalculated by Discovery in order to verify that the price provided by the provider is correct. ❚ If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of recent arm's length market transactions, reference to the current fair value of another instrument that is substantially the same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices obtained in actual market transactions. ❚ The fair value of the hedged derivatives is calculated as follows: (a) The fair value of call options is calculated on a Black-Scholes model; (b) The fair value of the return swaps is calculated by discounting the future cash flows of the instruments; and (c) The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based on observable yield curves. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 15 of 50 -- 15 ADDITIONAL DISCLOSURE continued for the six months ended 31 December 2021 EXCHANGE RATES USED IN THE PREPARATION OF THESE RESULTS USD GBP RMB 31 December 2021 – Average 15.03 20.49 2.33 – Closing 15.91 21.51 2.50 30 June 2021 – Average 15.42 20.74 2.32 – Closing 14.28 19.74 2.21 31 December 2020 – Average 16.28 21.27 2.40 – Closing 14.71 20.10 2.26 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 16 of 50 -- 16 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 17 SEGMENTAL INFORMATION for the six months ended 31 December 2021 1 The banking fee and commission consists of R180 million of revenue which is recognised over time, while interchange revenue of R211 million is recognised at a point in time. 2 The inter-segment funding of R341 million reflects a notional allocation of interest earned on the negative reserve backing policyholders' funds of guaranteed investment products and hence is transferred to Discovery Invest. 3 From the interim period ending 31 December 2021, intercompany investment income is presented separately. In previous periods, this amount was included in 'Investment income earned on shareholder investments and cash'. The previous reporting period has been restated to align presentation. 4 This segment relates to SA Insure – Personal lines. R million SA Health SA Life SA Invest SA Insure4 SA Vitality SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments5 IFRS TOTAL Income statement Insurance premium revenue 87 7 337 7 712 2 260 – – 5 606 3 359 3 256 29 617 (399) 29 218 Reinsurance premiums (1) (1 730) – (36) – – (714) (1 755) (69) (4 305) 399 (3 906) Net insurance premium revenue 86 5 607 7 712 2 224 – – 4 892 1 604 3 187 25 312 – 25 312 Fee income from administration businesses 3 818 – 1 388 9 – – 14 – 958 6 187 (7) 6 180 Vitality income – – – – 1 140 – 181 115 303 1 739 – 1 739 Net banking fee and commission income – – – – – 275 – – 5 280 – 280 Banking fee and commission income1 – – – – – 391 – – – 391 – 391 Banking fee and commission expense – – – – – (116) – – 5 (111) – (111) Net bank interest and similar income – – – – – 138 – – – 138 – 138 Bank interest and similar income using the effective interest rate – – – – – 377 – – – 377 – 377 Bank interest and similar expense using the effective interest rate – – – – – (239) – – – (239) – (239) Investment income earned on assets backing policyholder liabilities – 1 – 59 – – – 4 3 67 (67) – Finance charge on negative reserve funding – – – – – – – (168) – (168) 168 – Inter-segment funding2 – (341) 341 – – – – – – – – – Net fair value gains/(losses) on financial assets at fair value through profit or loss 13 293 6 223 3 1 3 (27) 159 966 7 634 696 8 330 Other income 572 7 – – – – 9 – 22 610 – 610 Net income 4 489 5 567 15 664 2 295 1 141 416 5 069 1 714 5 444 41 799 790 42 589 Net claims and policyholders’ benefits (20) (5 175) (6 224) (1 349) – – (2 228) (476) (472) (15 944) – (15 944) Claims and policyholders’ benefits (20) (8 395) (6 224) (1 349) – – (2 876) (1 149) (540) (20 553) 270 (20 283) Insurance claims recovered from reinsurers – 3 220 – – – – 648 673 68 4 609 (270) 4 339 Acquisition costs (12) (814) (592) (342) (46) – (481) (737) 131 (2 893) (168) (3 061) Marketing and administration expenses – depreciation and amortisation (47) (4) (5) (42) (6) (129) (241) (31) (377) (882) (84) (966) – derecognition of intangible assets and property and equipment – – – (6) – – – – – (6) – (6) – other expenses (2 659) (1 063) (573) (500) (1 050) (766) (1 871) (1 056) (1 467) (11 005) (70) (11 075) Expected credit losses – – – – – (19) – – – (19) – (19) Recovery of expenses from reinsurers – – – – – – 451 786 – 1 237 – 1 237 Net transfer to/from assets and liabilities under insurance contracts – change in assets arising from insurance contracts – 3 769 – – – – – (2 318) 35 1 486 2 633 4 119 – change in assets arising from reinsurance contracts – 62 – – – – (15) 7 4 58 (1) 57 – change in liabilities arising from insurance contracts (1) 439 (7 283) (21) – – 166 (11) (3 047) (9 758) (22) (9 780) – change in liabilities arising from reinsurance contracts – (846) – – – – – 2 483 – 1 637 (2 633) (996) Fair value adjustment to liabilities under investment contracts – (1) (470) – – – – – (574) (1 045) (531) (1 576) Share of net profits from equity-accounted investments – – – (20) – – – – 227 207 – 207 Normalised profit/(loss) from operations 1 750 1 934 517 15 39 (498) 850 361 (96) 4 872 (86) 4 786 Economic assumption adjustments net of discretionary margins and interest rate derivative – 498 – – – – – (46) – 452 70 522 Economic assumption adjustments net of discretionary margins – 498 – – – – – 24 – 522 – 522 Fair value losses on VitalityLife interest rate derivative – – – – – – – (70) – (70) 70 – Net fair value gains on financial assets at fair value through profit or loss – 34 16 – – – – 60 102 212 (212) – Investment income earned on shareholder investments and cash3 17 6 16 – 16 – 18 1 8 82 63 145 Intercompany investment income3 – – – – – – – 3 448 451 (451) – Gain on dilution and disposal of equity-accounted investments – – – 4 – – – – – 4 – 4 Expenses related to Prudential Book transfer – – – – – – – (92) – (92) 92 – Covid-19 vaccination programme – – – – – – – – (137) (137) 137 – Amortisation of intangibles from business combinations – – – – – – – – (30) (30) – (30) Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – – (83) (83) 83 – Finance costs (1) – – – – – (3) (50) (640) (694) (140) (834) Intercompany finance costs (145) – – – – – (3) (113) (195) (456) 456 – Foreign exchange gains 2 18 18 – – – – – 90 128 – 128 Profit/(loss) before tax 1 623 2 490 567 19 55 (498) 862 124 (533) 4 709 12 4 721 Income tax expense (448) (728) (159) (8) (16) 128 (186) (28) 41 (1 404) (12) (1 416) Profit/(loss) for the period 1 175 1 762 408 11 39 (370) 676 96 (492) 3 305 – 3 305 5 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following: – The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual arrangement as a reinsurance contract under IFRS 4. – Unit trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery's results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery's results, effectively being the income and expenses relating to units held by third parties. – The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments. – The effects of reclassifying items to align to IFRS results. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 17 of 50 -- 18 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 19 SEGMENTAL INFORMATION continued for the six months ended 31 December 2020 1 The banking fee and commission consists of R145 million of revenue which is recognised over time, while interchange revenue of R157 million is recognised at a point in time. 2 The inter-segment funding of R373 million reflects a notional allocation of interest earned on the negative reserve backing policyholders' funds of guaranteed investment products and hence is transferred to Discovery Invest. 3 In line with the current period disclosure, the prior period numbers were restated to separately present intercompany investment income. 4 This segment relates to SA Insure – Personal lines. 5 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following: R million SA Health SA Life SA Invest SA Insure4 SA Vitality SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments5 IFRS total Income statement Insurance premium revenue 155 6 709 7 230 1 979 – – 5 076 3 250 2 594 26 993 (454) 26 539 Reinsurance premiums (1) (1 617) – (31) – – (907) (1 683) (33) (4 272) 454 (3 818) Net insurance premium revenue 154 5 092 7 230 1 948 – – 4 169 1 567 2 561 22 721 – 22 721 Fee income from administration businesses 3 707 – 1 120 7 – 2 16 – 849 5 701 (6) 5 695 Vitality income – – – – 1 132 15 150 118 328 1 743 – 1 743 Net banking fee and commission income – – – – – 215 – – 4 219 – 219 Banking fee and commission income1 – – – – – 296 – – – 296 – 296 Banking fee and commission expense – – – – – (81) – – 4 (77) – (77) Net bank interest and similar income – – – – – 121 – – – 121 16 137 Bank interest and similar income using the effective interest rate – – – – – 302 – – – 302 – 302 Bank interest and similar expense using the effective interest rate – – – – – (181) – – – (181) 16 (165) Investment income earned on assets backing policyholder liabilities – 6 – 64 – – 1 1 1 73 (73) – Finance charge on negative reserve funding – – – – – – – 86 – 86 (86) – Inter-segment funding2 – (373) 373 – – – – – – – – – Net fair value gains/(losses) on financial assets at fair value through profit or loss 5 389 4 167 6 – 83 38 (105) 540 5 123 390 5 513 Other income 434 1 – – – 41 14 – 9 499 – 499 Receipts arising from reinsurance contracts – 500 – – – – – – – 500 – 500 Net income 4 300 5 615 12 890 2 025 1 132 477 4 388 1 667 4 292 36 786 241 37 027 Net claims and policyholders' benefits (62) (3 619) (5 938) (1 073) – – (1 809) (360) (286) (13 147) – (13 147) Claims and policyholders' benefits (62) (5 123) (5 938) (1 072) – – (2 420) (899) (316) (15 830) 226 (15 604) Insurance claims recovered from reinsurers – 1 504 – (1) – – 611 539 30 2 683 (226) 2 457 Acquisition costs (19) (798) (493) (285) (29) – (427) (983) 65 (2 969) 86 (2 883) Marketing and administration expenses – depreciation and amortisation (58) (4) (5) (34) (7) (130) (212) (29) (337) (816) (105) (921) – derecognition of intangible assets and property and equipment – – – (3) – – – – – (3) – (3) – other expenses (2 491) (988) (487) (463) (1 050) (730) (1 608) (765) (1 203) (9 785) (115) (9 900) Expected credit losses – – – – – (228) – – – (228) – (228) Recovery of expenses from reinsurers – – – – – – 404 913 – 1 317 – 1 317 Transfer to/from assets and liabilities under insurance contracts – change in assets arising from insurance contracts – 2 627 – – – – – 231 39 2 897 (39) 2 858 – change in assets arising from reinsurance contracts – 35 – – – – 47 5 – 87 – 87 – change in liabilities arising from insurance contracts – (111) (5 227) (56) – – (169) (9) (2 680) (8 252) 86 (8 166) – change in liabilities arising from reinsurance contracts – (834) – – – – – (343) – (1 177) 39 (1 138) Fair value adjustment to liabilities under investment contracts – (1) (269) – – – – – (88) (358) (849) (1 207) Share of net profits from equity-accounted investments – – – (4) – – (1) – 160 155 – 155 Normalised profit/(loss) from operations 1 670 1 922 471 107 46 (611) 613 327 (38) 4 507 (656) 3 851 Investment income earned on shareholder investments and cash3 21 4 17 – 21 – – 3 11 77 73 150 Intercompany investment income3 – – – – – – – 3 325 328 (328) – Economic assumption adjustments net of discretionary margins and interest rate derivative – (493) – – – – – 1 – (492) 317 (175) Economic assumption adjustments net of discretionary margins – (493) – – – – – 318 – (175) – (175) Fair value gains on VitalityLife interest rate derivatives – – – – – – – (317) – (317) 317 – Net fair value gains on financial assets at fair value through profit or loss – 79 (3) – – – – (47) (211) (182) 182 – Restructuring costs – – – – – – – (25) – (25) 25 – Expenses related to Prudential Book transfer – – – – – – – (96) – (96) 96 – Amortisation of intangibles from business combinations – – – – – – – – (35) (35) – (35) Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – – (124) (124) 124 – Finance costs (4) – – – – – (1) (36) (608) (649) (177) (826) Intercompany finance costs (128) – – – – – (3) (126) (71) (328) 328 – Foreign exchange losses (14) – (28) – – – – – (320) (362) – (362) Profit/(loss) before tax 1 545 1 512 457 107 67 (611) 609 4 (1 071) 2 619 (16) 2 603 Income tax expense (436) (455) (126) (31) (20) 147 (120) 11 286 (744) 16 (728) Profit/(loss) for the period 1 109 1 057 331 76 47 (464) 489 15 (785) 1 875 – 1 875 – The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual arrangement as a reinsurance contract under IFRS 4. – Unit trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery's results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery's results, effectively being the income and expenses relating to units held by third parties. – The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments. – The effects of reclassifying items to align to IFRS results. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 18 of 50 -- 20 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 21 REVIEW OF GROUP RESULTS for the six months ended 31 December 2021 ADDITIONAL INFORMATION NORMALISED PROFIT FROM OPERATIONS The following table shows the main components of the normalised profit from operations, per composite, for the six months ended 31 December 2021: South Africa United Kingdom Vitality Global Total R million DECEMBER 2021 December 2020 % change DECEMBER 2021 December 2020 % change DECEMBER 2021 December 2020 % change DECEMBER 2021 December 2020 % change Discovery Health 1 750 1 670 5 – – – – – – 1 750 1 670 5 Discovery Life 1 934 1 922 1 – – – – – – 1 934 1 922 1 Discovery Invest 517 471 10 – – – – – – 517 471 10 Discovery Vitality 39 46 (15) – – – – – – 39 46 (15) VitalityHealth – – – 850 613 39 – – – 850 613 39 VitalityLife – – – 361 327 10 – – – 361 327 10 Normalised profit from established businesses 4 240 4 109 3 1 211 940 29 – – – 5 451 5 049 8 Discovery Insure (Personal lines) 15 107 (86) – – – – – – 15 107 (86) Vitality Group1 – – – – – – 234 238 (2) 234 238 (2) Ping An Health1 – – – – – – 140 112 25 140 112 25 Normalised profit from emerging businesses2 15 107 (86) – – – 374 350 7 389 457 (15) Discovery Bank (498) (611) 18 – – – – – – (498) (611) 18 Other new initiatives1, 3 (175) (151) (16) (101) (89) (13) (194) (148) (31) (470) (388) (21) Normalised loss from new initiatives (673) (762) 12 (101) (89) (13) (194) (148) (31) (968) (999) 3 Normalised profit from operations4 3 582 3 454 4 1 110 851 30 180 202 (11) 4 872 4 507 8 1 Included in 'All other segments' in the Segmental information. 2 Emerging businesses are those businesses that have achieved sufficient scale to be profitable or profitable in the near future, although not yet significant in cash generation for the Group and likely to require funds to support new business growth. 3 Other new initiatives include costs of start-up businesses and expenses incurred to investigate, research and develop new products and markets. Start-up costs include costs in relation to, amongst others, the UK investment business VitalityInvest, a commercial offering in Discovery Insure, an Umbrella Fund offering in Discovery Invest and the Vitality1 platform being a leading behavioural change platform enabling shared-value insurance and financial services products across the Discovery Group. Certain unallocated head office costs are also included in this segment. 4 The amount can be further analysed by referencing to Normalised profit/(loss) from operations as per the Segment Total in the Segmental information. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 19 of 50 -- 22 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 ADDITIONAL INFORMATION continued EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS Change in presentation of reconciliation of headline earnings and normalised headline earnings For the six months ended 31 December 2021, the headline earnings and normalised headline earnings reconciliations have been amended to enhance the presentation thereof. The presentation of prior periods have been restated accordingly to enable comparability. R million GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited % change Group Year ended June 2021 Audited Earnings per share (cents): – basic 498.8 280.2 78 480.7 – diluted 492.5 277.8 77 475.4 Headline earnings per share (cents): – basic 499.1 280.3 78 454.7 – diluted 492.7 277.9 77 449.7 Normalised headline earnings per share (cents): – basic 437.7 347.9 26 518.7 – diluted 432.2 344.9 25 512.9 Number of shares used in calculation Weighted number of shares in issue ('000) 656 862 656 668 656 710 Diluted weighted number of shares ('000) 665 290 662 422 664 073 Headline earnings reconciliation Headline earnings per share is disclosed per the JSE Listing Requirements and is calculated in accordance with the circular titled Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares in issue. GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited % Group Year ended June 2021 Audited R million GROSS TAX NET Gross Tax Net change Net Profit attributable to the ordinary shareholders 3 277 1 841 78 3 157 Adjusted for: – loss on derecognition of property and equipment 6 (2) 4 3 (1) 2 9 – gain on disposal of property and equipment – – – (1) – (1) (2) – impairment of property and equipment – – – – – – 15 – gain on dilution and disposal of equity-accounted investments (4) 1 (3) – – – (414) – impairment of equity-accounted investments – – – – – – 149 – loss on derecognition of intangible assets – – – – – – 31 – impairment of other intangible assets – – – – – – 41 Headline earnings 3 278 1 842 78 2 986 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 20 of 50 -- 23 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 ADDITIONAL INFORMATION continued Normalised headline earnings reconciliation Normalised headline earnings is calculated per Discovery's policy as set out in the Accounting Policies at the end of the results announcement. GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited % change Group Year ended June 2021 Audited R million GROSS TAX NET Gross Tax Net Net Headline earnings 3 278 1 842 78 2 986 Adjusted for: – economic assumption adjustments net of discretionary margins and interest rate derivatives (452) 131 (321) 492 (138) 354 383 – (gain)/loss on economic assumption adjustments net of discretionary margins (522) 144 (378) 175 (77) 98 (677) – loss on fair value changes on VitalityLife interest rate derivatives 70 (13) 57 317 (61) 256 1 060 – other (129) 48 (81) 314 (226) 88 37 – amortisation of intangible assets arising from business combinations 30 (6) 24 35 (8) 27 53 – recognition of deferred tax assets on assessed losses not recognised in previous periods – – – – (146) (146) (152) – (gain)/loss on fair value changes on foreign exchange contracts not designated as hedges (99) 28 (71) 207 (58) 149 219 – (gain)/loss on fair value changes on swaption contract in VitalityLife (60) 11 (49) 47 (9) 38 (113) – restructuring costs – – – 25 (5) 20 27 – transaction costs related to the VitalityLife interest rate derivative – – – – – – 3 – increase in deferred tax balances resulting from use of different tax rates on items that were excluded from normalised headline earnings – 15 15 – – – – Normalised headline earnings 2 876 2 284 26 3 406 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 21 of 50 -- 24 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS PROVISION AND RESERVES FOR EXPECTED COVID-19 At 30 June 2021, Discovery had reserved R3.1 billion, for both future claims and lapses as a result of the COVID-19 pandemic. This estimation reflected management’s best estimate of the impact as at 30 June 2021. The COVID-19 provisions comprise of provisions made in Discovery Life and VitalityLife and unearned premium reserves in VitalityHealth. Due to the utilisation of the available discretionary margin, some of these provisions are accounted for against the discretionary margins in accordance with IFRS and Discovery’s accounting policy. Although the allowance for the COVID-19 impact is an abnormal provision for future impacts, it is not excluded in the presentation of normalised headline earnings because it is seen as part of the core operations and will impact future cash flows. R million GROUP SIX MONTHS ENDED DECEMBER 2021 UNAUDITED Group Six months ended December 2020 Unaudited Group Year ended June 2021 Audited At beginning of the period 3 080 3 442 3 442 – Provisions 2 800 2 729 2 729 – Unearned premium reserve 280 713 713 Movements: (2 211) (86) (362) Unwinding, utilisation and release of provisions (2 238) (1 116) (1 886) Provisions made/(released) during the period, including in respect of new business (5) 542 2 177 Net movement in unearned premium reserve 25 357 (433) Other 7 131 (220) At end of the period 869 3 356 3 080 – Provisions 564 2 293 2 800 – Unearned premium reserve 305 1 063 280 CLAIMS EXPERIENCE FROM CIVIL UNREST JULY 2021 The claims arising from the July 2021 unrest in both personal lines and business lines of Discovery Insure were fully settled from the SASRIA fund, with no loss to Discovery. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 22 of 50 -- 25 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued bORROWINGS AT AMORTISED COST R million Reference DECEMBER 2021 June 2021 Borrowings from Banks and listed debt 15 550 15 230 – United Kingdom borrowings i 3 385 3 764 – South African borrowings ii 12 165 11 466 Lease liabilities 4 254 4 263 – 1 Discovery Place 3 387 3 388 – Other lease liabilities 867 875 Total borrowings at amortised cost 19 804 19 493 i. United Kingdom borrowings Facility amount GBP million Variable rate Capital repayment and maturity date Carrying value GBP/Rand million DECEMBER 2021 June 2021 GBP R GBP R 80 3-month Libor + 265bps1 Instalments – 31 July 2023 58 1 241 73 1 435 28 3-month Libor + 100bps1, 2 At maturity – 18 April 2022 – – 26 512 75 3-month Libor + 229bps1 At maturity – 31 July 2023 98 2 144 89 1 817 183 156 3 385 188 3 764 1 Interest payable quarterly in arrears. 2 This is a revolving facility. Total finance cost for the UK borrowings for the six months ended 31 December 2021 was GBP 2.8 million (R57 million) (31 December 2020: GBP 3.2 million (R65 million)). 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 23 of 50 -- 26 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued BORROWINGS AT AMORTISED COST continued ii. South African borrowings CREDIT RATING Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s Global scale long term issuer rating at Ba3 on 15 November 2021. In line with the country’s outlook, the credit outlook assigned by Moody’s remains negative. The national scale long term issuer rating of Discovery was reaffirmed at A1.za. DISCOVERY LIMITED Facility amount R million Variable rate Interest rate per annum Capital repayment and maturity date Carrying value R million DECEMBER 2021 June 2021 Listed DMTN4 500 3-month Jibar + 161bps 9.71%1,3 At maturity – 21 November 2022 503 503 500 3-month Jibar + 205bps 6.30%1,3 At maturity – 21 August 2023 503 503 200 – 10.46%2 At maturity – 21 November 2024 202 202 800 3-month Jibar + 191bps 10.31%1,3 At maturity – 21 November 2024 804 804 1 200 3-month Jibar + 191bps 9.21%1,3 At maturity – 21 November 2024 1 218 1 220 700 3-month Jibar + 180bps 10.29%1,3 At maturity – 21 August 2026 704 703 300 3-month Jibar + 180bps 9.40%1,3 At maturity – 21 August 2026 302 302 Unlisted DMTN4 1 100 – 8.92%3 At maturity – 10 March 2023 1 104 1 103 2 500 – 9.62%3 At maturity – 22 February 2025 2 519 2 519 Other 1 000 3-month Jibar + 245bps 10.28%1,3 At maturity – 02 March 2023 1 000 999 500 3-month Jibar + 86bps 5.85% At maturity – 30 June 2022 674 659 1 400 – 4.93%3 At maturity – 12 April 2022 699 – 10 700 10 232 9 517 1 The interest rate has been fixed through interest rate swaps. 2 Interest is payable semi-annually in arrears. 3 Interest payable quarterly in arrears. 4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 24 of 50 -- 27 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued bORROWINGS AT AMORTISED COST continued DISCOVERY CENTRAL SERVICES Facility amount R million Interest rate per annum Capital repayment and maturity date Carrying value R million DECEMBER 2021 June 2021 1 400 10.60%1 At maturity – 20 December 2023 1 421 1 423 650 11.56%2 Instalments – 29 October 2027 512 526 2 050 1 933 1 949 1 Interest payable quarterly in arrears. 2 Instalments of interest and capital is monthly. Total finance cost for South African borrowings and related hedges for the six months ended 31 December 2021 was R563 million (31 December 2020: R544 million). CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS The Group’s capital is defined as capital and reserves attributable to shareholders as presented on the consolidated statement of financial position. The Group’s objectives when managing capital are: ❚ To comply with the statutory capital requirements required by the regulators of the insurance markets where the Group operates; refer to Capital section below for the statutory capital requirements. ❚ To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory requirement in the event of deviations from the main assumptions affecting the Group’s insurance businesses. ❚ To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements. ❚ To achieve an optimal and efficient capital funding profile; and ❚ To consider capital management needs both in the short term and over a five-year planning horizon. Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the Group. A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares, debt, reinsurance arrangements and other hybrid instruments. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 25 of 50 -- 28 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS FINANCIAL LEVERAGE RATIO As part of the capital management process, the Group monitors its capital structure utilising the Financial Leverage Ratio (FLR). This ratio is calculated as total debt1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of below 28% per the Group Risk Appetite statement. However, the 28% is merely a risk appetite indicator, and doesn’t necessarily indicate any form of a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR position: R million DECEMBER 2021 June 2021 – Borrowings at amortised cost1 15 550 15 230 – Guaranteed deposit facilities 800 800 Total debt and guarantees1 16 350 16 030 Total equity 52 175 46 419 Financial Leverage Ratio (%) 23.9% 25.7% 1 Excluding all IFRS 16 lease liabilities of R4 254 million (June 2021: R4 263 million). The FLR at 31 December 2021 is in line with Discovery’s risk appetite. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 26 of 50 -- 29 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS continued CAPITAL For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required capital must be maintained at all times throughout the period. With effect from 1 July 2018, the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards were implemented in South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while Vitality Health and Vitality Life are regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016. The table below summarises the capital requirements on the statutory basis, across the Group subsidiaries, and the actual solvency capital held in relation to this requirement. DECEMBER 2021 June 2021 STATUTORY CAPITAL REQUIREMENTS COVER Statutory capital requirements Cover Discovery Life R19 205 million 1.8 times R17 647 million 1.8 times Discovery Insure R935 million 1.8 times R1 079 million 1.8 times Vitality Health GBP109.2 million (R2 348 million) 1.9 times GBP 105.6 million (R2 084 million) 1.6 times Vitality Life GBP257.3 million (R5 533 million) 2.2 times GBP 225.5 million (R4 451 million) 2.4 times As communicated in the results for the year ended 30 June 2021, Ping An Health Insurance Company of China Limited (PAH) required additional capital for future growth and in response to new Chinese prudential regulatory requirements. During the period under review, Discovery has advanced R1.5 billion to PAH in proportion to Discovery’s 24.99% shareholding. While this was funded in the interim by way of a bridge facility and internal resources, as explained in the previous reporting period, Discovery still anticipates raising a specific quantum of equity capital for this purpose in line with the disciplined framework of the capital plan. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 27 of 50 -- 30 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 SHAREHOLDER INFORMATION DIRECTORATE Changes to the Board of Discovery Limited from 1 July 2021 to the date of this announcement are as follows: ❚ Ms M Hlahla has been appointed as an independent non-executive director with effect from 15 August 2021. Ms M Hlahla is a member of the Audit Committee, Remuneration Committee, and Social and Ethics Committee. Ms Hlahla's appointment strengthens the independence and business skills on the board and the committees. ❚ Ms SE De Bruyn, an independent non-executive director, retired, effective 24 November 2021. Ms De Bruyn has served as an independent non-executive director of the Company since 2005 and has served as the chairperson of the Remuneration Committee and as a member of the Audit Committee. Ms De Bruyn has also retired as a non-executive director of Discovery Life Limited, Discovery Health (Pty) Ltd and Discovery Vitality (Pty) Ltd. ❚ Dr BA Brink, an independent non-executive director, retired, effective 24 November 2021. Dr Brink has served as an independent non-executive director of the Company since 2004 and has served as a member of the Treating Customers Fairly Subcommittee, Social and Ethics Committee as well as the Risk and Compliance Committee. Dr Brink has also retired as a non-executive director of Discovery Health (Pty) Ltd and Discovery Vitality (Pty) Ltd. ❚ Ms F Khanyile, an independent non-executive director, has been appointed as Chairperson of the Remuneration Committee following the retirement of Ms SE De Bruyn. DIVIDEND Final dividends paid in respect of the 2021 financial year The following final dividends were paid during the current period: ❚ B preference share dividend of 347.12329 cents per share (277.69863 cents net of dividend withholding tax), paid on Monday 27 September 2021. ❚ Discovery had not recommended the payment of final ordinary dividends for the year ended 30 June 2021. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 28 of 50 -- 31 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued DEbT COVENANTS The following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial covenants. DECEMBER 2021 June 2021 Debt covenant and explanation Minimum requirement Group Debt to EBITDA Ratio: Less than 2.5 times 2.16 2.31 – Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the 1 Discovery Place (‘1 DP’) lease and includes guarantees issued to third parties. – EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1DP and excludes such items deemed extraordinary, such as economic assumption adjustments, and specified FinRe arrangements. Group financial indebtedness to embedded value Less than 30% of Group 20.8% 22.6% – Group financial indebtedness is as per Group Debt in the calculation. Embedded value Discovery Life Statutory Capital Requirement (SCR) Cover SCR cover must be more than 1.1 1.84 times 1.83 times Group embedded value Greater than R30 billion ZAR ZAR 82 916 million 74 713 million New business embedded value must not be negative Positive value of new business for 3 consecutive 6-month periods Dec 2021: R937 million June 2021: R946 million Dec 2020: R945 million June 2021: R946 million Dec 2020: R945 million June 2020: R726 million 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 29 of 50 -- 32 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued CONSOLIDATION OF UNIT TRUSTS WHICH THE GROUP CONTROLS Unit Trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery’s results for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds. Assets and liabilities of these Unit Trusts increased by R2 463 million respectively, compared to the prior financial year, with movements in the following line items on the Group’s Statement of Financial Position: Changes in assets ❚ Investments at fair value through profit or loss increased by R2 475 million. ❚ Cash and cash equivalents increased by R304 million. ❚ Insurance receivables, contract receivables and other non-financial receivables decreased by R310 million. ❚ Other assets decreased by R6 million. Changes in liabilities ❚ Investment contracts at fair value through profit or loss increased by R2 783 million. ❚ Other liabilities decreased by R320 million. As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders. There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The cash flow impact of the movement in policyholder investments for the period is included in the following line items on the Group’s Statement of cash flows: ❚ Purchase of investments held to back policyholder liabilities includes cash outflows of R30 687 million. ❚ Proceeds from the disposal of investments held to back policyholder liabilities includes cash inflows of R28 374 million. MATERIAL TRANSACTIONS WITH RELATED PARTIES Discovery Long Term-Incentive Plan Trust At the annual general meeting held on 28 November 2019, the shareholders approved the establishment of the Discovery Long- Term Incentive Plan Trust (Trust) with the purpose, inter-alia, to subscribe, purchase and/or otherwise acquire and hold Discovery ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the requirements of the Trust. During December 2021, 3 194 870 (2020: 7 477 865) new shares were issued by Discovery Limited to the Trust (2020: the allocation represented the allocation of 2019 and 2020) at a value of R443 million (2020: R907 million), with a par value of 0.01 cents per share. While held in the Trust, these shares are treated as treasury shares and not treated as issued. MAJOR CUSTOMERS AND OTHER DISCOVERY ENTITIES NOT PART OF DISCOVERY GROUP Discovery Health Medical Scheme (DHMS) Discovery Health administers DHMS and provides managed care services for which it charges an administration fee and a managed healthcare fee respectively. These fees are determined on an annual basis and approved by the independent trustees of DHMS. The fees totalled R3 271 million for the six months ended 31 December 2021 (2020: R3 140 million). In addition, Discovery offers the members of DHMS access to the Vitality programme. REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 30 of 50 -- 33 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 SHAREHOLDER INFORMATION continued Interim dividend declaration in respect of the 2022 financial year b PREFERENCE SHARE CASH DIVIDEND DECLARATION: On 18 February 2022, the directors declared an interim gross cash dividend of 355.75342 cents (284.60274 cents net of dividend withholding tax) per B preference share for the period 1 July 2021 to 31 December 2021, payable from the income reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The issued preference share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend will be as follows: Last day of trade to receive a dividend Tuesday, 8 March 2022 Shares commence trading “ex” dividend Wednesday, 9 March 2022 Record date Friday, 11 March 2022 Payment date Monday, 14 March 2022 B Preference share certificates may not be dematerialised or rematerialised between Wednesday, 9 March 2022 and Friday, 11 March 2022. ORDINARY SHARE CASH DIVIDEND DECLARATION: Given the remaining uncertainty caused by the COVID-19 pandemic, Discovery will not be recommending the payment of interim ordinary dividends. The reintroduction of dividends will be considered when appropriate. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 31 of 50 -- 34 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 REVIEW OF GROUP RESULTS continued for the six months ended 31 December 2021 ACCOUNTING POLICIES NORMALISED HEADLINE EARNINGS Discovery assesses its performance using Normalised Headline Earnings, an alternative non-IFRS profit measure, alongside its IFRS profit. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and understanding of the financial performance of the Group. Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures and disclosures provided by other entities. Discovery calculates headline earnings in accordance with the latest SAICA Circular ’Headline Earnings’. NHEPS is calculated by starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal operations as follows: ❚ Once-off transactions, for example restructuring costs, initial costs related to the Prudential book transfer, transaction costs related to interest rate derivatives and initial deferred tax assets raised on previously unrecognised assessed losses; ❚ Unusual items – Discovery considers items to be unusual when they have limited predictive value and it is reasonable that items of similar nature would not necessarily arise for several future annual reporting periods. These adjustments include those gains or losses impacting profit or loss associated with changes in economic assumptions recognised in profit or loss, net of any gains or losses on derivatives to offset such changes in economic assumptions; or ❚ Income or expenses not considered to be part of Discovery’s normal operations, for example amortisation of intangibles from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges. Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency. bASIS OF PREPARATION Statement of compliance Discovery Limited is a company incorporated in South Africa. The unaudited condensed consolidated interim financial statements for the six months ended 31 December 2021 (interim results) consolidate the results of Discovery and its subsidiaries (together the Group) and equity account the Group’s interest in associates and joint ventures. The interim results comprise the condensed consolidated statement of financial position at 31 December 2021, condensed consolidated income statement, condensed consolidated statement of comprehensive, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six months ended 31 December 2021 and selected explanatory notes. The interim results have been prepared in accordance with the JSE Limited Listing and Debt Listing Requirements, International Financial Reporting Standards (IFRS) including IAS 34 Interim Financial Reporting, the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council as well as the requirements of the South African Companies Act 71 of 2008. The accounting policies adopted are consistent with the accounting policies applied in the prior Annual Financial Statements. Amendments to standards effective from 1 July 2021 do not have a material effect on the Group’s interim results. These interim results do not include all the notes typically included in the annual financial statements and should therefore be read in conjunction with the Group audited consolidated financial statements for the year ended 30 June 2021. External review and comparative information The interim results for the six months ended 31 December 2021 have not been reviewed or audited by the Group’s independent auditors PricewaterhouseCoopers Inc. and KPMG Inc. Comparative information for the six months ended 31 December 2020 was not reviewed by the Group’s independent auditors. Comparative information presented at and for the year ended 30 June 2021 within these financial statements has been correctly extracted from the Group’s audited consolidated financial statements for the year ended 30 June 2021. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 32 of 50 -- 35 EMBEDDED VALUE STATEMENT for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 The embedded value of Discovery consists of the following components: ❚ the adjusted net worth attributed to the business at the valuation date; ❚ plus: the present value of expected future shareholder cash flows from the in-force covered business; ❚ less: the cost of required capital. The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate. The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements. The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new business written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of required capital. The value of new business is calculated using the current reporting date assumptions. The embedded value includes the insurance and administration profits of the covered business in the Discovery Limited Group. Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health, AIA Health, Discovery Insure, Discovery Bank, VitalityInvest and Umbrella Funds, no published value has been placed on the current in-force business as the businesses have not yet reached suitable scale with predictable experience. In August 2011, Discovery raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth. The 31 December 2021 embedded value results and disclosures were not subjected to an external review. -- 33 of 50 -- 36 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 1: GROUP EMBEDDED VALUE R million 31 DECEMBER 2021 31 December 2020 % change 30 June 2021 Shareholders’ funds 52 175 45 135 16 46 419 Adjustment to shareholders’ funds from published basis1 (38 378) (32 996) (34 184) Adjusted net worth2 13 797 12 139 12 235 Value of in-force covered business before cost of required capital 74 679 66 010 67 175 Cost of required capital (5 556) (5 682) (4 765) Discovery Limited embedded value 82 920 72 467 14 74 645 Number of shares (millions) 656.9 656.8 656.8 Embedded value per share R126.23 R110.33 14 R113.65 Diluted number of shares (millions) 668.3 665.1 665.1 Diluted embedded value per share3 R124.08 R108.96 14 R112.23 1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing exchange rate of R21.51/GBP (June 2021: R19.74/GBP; December 2020: R20.10/GBP). R million 31 DECEMBER 2021 31 December 2020 30 June 2021 Life net assets under insurance contracts (23 033) (19 785) (20 675) Vitality Life Limited and Discovery funded VitalityLife business on the Prudential licence net assets under insurance contracts (8 944) (6 427) (7 703) VitalityHealth financial reinsurance asset (2 855) (3 005) (2 353) VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) (415) (439) (407) VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (12) (16) (12) Goodwill relating to the acquisition of Standard Life Healthcare and the Prudential joint venture (2 661) (2 487) (2 442) Intangible assets (net of deferred tax) in covered businesses (869) (867) (830) Net preference share capital (779) (779) (779) Reversal of 1 Discovery Place IAS 17 financial lease accounting 1 079 871 975 Equity settled share based payment provision adjustment 111 (62) 42 (38 378) (32 996) (34 184) The “equity settled share based payment provision adjustment” reflects the difference between the provision in the IFRS equity and the mark-to- market value of the equity settled share based payments. -- 34 of 50 -- 37 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value: R million 31 DECEMBER 2021 31 December 2020 30 June 2021 Shareholders’ funds 52 175 45 135 46 419 Adjustment to shareholders' funds (38 378) (32 996) (34 184) Adjusted net worth 13 797 12 139 12 235 Excess of available capital over adjusted net worth 34 851 26 659 30 718 Available capital 48 648 38 798 42 953 Required capital 36 388 31 951 32 699 Excess available capital 12 260 6 847 10 254 The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes: ◼ The net preference share capital of R779 million which is included as available capital. ◼ The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth and adds back the negative reserves eliminated on the Discovery funded VitalityLife business on the Prudential licence. ◼ The difference between Life’s Pillar 1 Own Funds and its adjusted net worth. The following table sets out the required capital for each of the covered businesses: R million 31 DECEMBER 2021 31 December 2020 30 June 2021 Health and Vitality 961 960 973 Life and Invest 24 006 20 440 22 059 VitalityHealth 3 171 2 877 2 847 VitalityLife 8 250 7 674 6 820 Total Required Capital 36 388 31 951 32 699 ◼ For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. ◼ For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement. ◼ For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement. ◼ For the VitalityLife business on the Prudential licence, the required capital was set equal to the UK Solvency I long-term insurance capital requirement as per the agreement with Prudential up to the Part VII transfer, thereafter it is set equal to 1.5 times the Solvency II Pillar 1 Solvency Capital Requirement. For the business sold on the Vitality Life Limited licence, the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement up to the Part VII transfer and 1.5 times thereafter. 3 The diluted embedded value per share adjusts for treasury shares held in the Discovery BEE Share Trust and as part of Discovery’s Long-term Incentive Plan where the impact is dilutive. -- 35 of 50 -- 38 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS R million VALUE BEFORE COST OF REQUIRED CAPITAL COST OF REQUIRED CAPITAL VALUE AFTER COST OF REQUIRED CAPITAL at 31 December 2021 Health and Vitality 23 844 (449) 23 395 Life and Invest1 31 342 (1 351) 29 991 VitalityHealth2 9 545 (514) 9 031 VitalityLife2 9 948 (3 242) 6 706 Total 74 679 (5 556) 69 123 at 31 December 2020 Health and Vitality 22 624 (408) 22 216 Life and Invest1 25 612 (1 081) 24 531 VitalityHealth2 9 474 (481) 8 993 VitalityLife2 8 300 (3 712) 4 588 Total 66 010 (5 682) 60 328 at 30 June 2021 Health and Vitality 22 503 (422) 22 081 Life and Invest1 27 777 (1 183) 26 594 VitalityHealth2 8 230 (462) 7 768 VitalityLife2 8 665 (2 698) 5 967 Total 67 175 (4 765) 62 410 1 Included in the Life and Invest value of in-force covered business is R1 834 million (June 2021: R1 675 million; December 2020: R1 543 million) in respect of investment management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth. 2 The value of in-force has been converted using the closing exchange rate of R21.51/GBP (June 2021: R19.74/GBP; December 2020: R20.10/GBP). -- 36 of 50 -- 39 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 3: GROUP EMBEDDED VALUE EARNINGS Six months ended R million 31 DECEMBER 2021 31 December 2020 30 June 2021 Embedded value at end of period 82 920 72 467 74 645 Less: embedded value at beginning of period (74 645) (70 834) (70 834) Increase in embedded value 8 275 1 633 3 811 Net change in capital1 (443) (909) (914) Dividends paid 28 34 63 Transfer to hedging reserve (116) (77) (260) Employee share option schemes (164) (121) (330) Increase in treasury shares 443 907 907 Embedded value earnings 8 023 1 467 3 277 Annualised return on opening embedded value 22.7% 4.2% 4.6% 1 The net change in capital reflects share issues (net of costs) and an increase (decrease) in treasury shares in the period. -- 37 of 50 -- 40 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS Six months ended 31 December 2021 Six months ended 31 December 2020 Year ended 30 June 2021 R million Net worth Cost of required capital Value of in-force covered business EMBEDDED VALUE Embedded value Embedded value Total profit from new business (at point of sale) (2 412) (126) 3 474 936 945 1 891 Profit from existing business ◼ Expected return 1 824 97 1 297 3 218 3 189 6 421 ◼ Change in methodology and assumptions1 1 689 (366) (1 076) 247 (1 931) (5 556) ◼ Experience variances 399 (99) 2 232 2 532 2 238 4 917 Impairment, amortisation and fair value adjustment2 (6) – – (6) (7) (14) Increase in goodwill and intangibles (188) – – (188) (156) (336) Other initiative costs3, 5 (238) – 13 (225) (444) (288) Non-recurring expenses (15) – – (15) (12) (85) Acquisition costs4 (18) – (1) (19) (9) (40) Finance costs 5, 6 (1 146) – – (1 146) (958) (2 104) Foreign exchange rate movements6 1 040 (298) 1 565 2 307 (1 851) (2 316) Other7 (15) 1 – (14) – (8) Return on shareholders' funds5, 8 396 – – 396 463 795 Embedded value earnings 1 310 (791) 7 504 8 023 1 467 3 277 1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements). 2 This item reflects the amortisation of the intangible assets reflecting the banking costs and capital expenditure in VitalityInvest and Discovery Group Europe Limited. The prior period comparatives include the amortisation of the intangible asset raised under the PrimeMed acquisition, which has since been dissolved. 3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health) and costs of start-up businesses (including Discovery Bank, VitalityInvest, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which relate to non-covered business are also included in this item. 4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the costs are not deducted from the value of new business. 5 This item excludes finance costs relating to intercompany loans between entities within the Group. The corresponding investment return earned on these intercompany loans is therefore also excluded from the return on shareholders’ funds line. 6 This item includes foreign exchange gains / (losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value of in-force. 7 This item includes, among other items, the tax benefits or losses that will emerge as the VitalityHealth DAC and intangible software assets amortise or increase. 8 The return on shareholders’ funds is shown net of tax and management charges. -- 38 of 50 -- 41 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 5: EXPERIENCE VARIANCES Health and Vitality Life and Invest VitalityHealth VitalityLife R million Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force TOTAL Renewal expenses 126 – 6 – (69) – (3) – 60 Other expenses – – – – – – – – – Lapses and surrenders1 11 190 (40) 315 – 323 (157) 275 917 Mortality and morbidity2 – – (100) (20) 528 – (13) – 395 Policy alterations1 – 21 (197) 192 – – 8 – 24 Backdated cancellations – – – – – – – – – Premium and fee income 57 – (44) (84) 24 – 9 2 (36) Economic3 – – 17 572 – – – – 589 Commission – – – – 22 – – – 22 Tax4 47 – (31) 198 (10) – (11) – 193 Reinsurance – – – – 48 – (35) 12 25 Maintain modelling term5 – 143 – 54 – 34 – – 231 Vitality benefits 28 – – – – – 13 – 41 Other6 (5) (1) 46 (10) 39 – 85 (83) 71 Total 264 353 (343) 1 217 582 357 (104) 206 2 532 1 For Life and Invest, the combined lapse and surrender experience and policy alterations experience is relative to assumptions which include an allowance for a short-term stress previously set in response to deteriorating experience from COVID-19 related impacts. For VitalityLife, large favourable variances from lower lapses were partially offset by higher in-period commission. 2 The mortality and morbidity experience for Life and Invest reflects a strain mainly due to non-COVID-19 morbidity experience. All confirmed COVID-19 claims were offset against the provision previously set and have been in line with expectation. For VitalityHealth, while claim incidence was at normal levels, claims severity was lower than assumed for the period under review due predominantly to clinical risk management interventions. There continue to be material uncertainties about future claims severity, with potential increases resulting from delayed treatments or undiagnosed disease during the pandemic. 3 The experience for Life and Invest arises largely due to higher than expected linked asset growth for the period under review, as well as a shift to investment in domestic equity from cash within the underlying asset classes. 4 The tax variance arises due to the timing difference between the expected tax payments and actual payments. 5 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises because the total term of the in-force covered business is effectively increased by six months. 6 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the VitalityHealth and VitalityLife segments which are not part of covered business, and movements in the value of the swaption in VitalityLife. -- 39 of 50 -- 42 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES Health and Vitality Life and Invest VitalityHealth VitalityLife R million Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force TOTAL Modelling changes1 – – – (154) – – 3 (2) (153) Administration fees – – – – – – – – – Expenses2 – (323) (2) 3 – – 6 (6) (322) Lapses – – – – – – – – – Mortality and morbidity – – – – – – – – – Benefit changes – – – – – – – – – Vitality – – – – – – – – – Tax – – – – – – – – – Economic assumptions3 – 5 (34) 501 – – (39) (339) 94 Premium and fee income4 – 560 – – – – – – 560 Reinsurance and financing5 – – 1 754 (1 643) – (14) 1 (5) 93 Other – – – (25) – – – – (25) Total – 242 1 718 (1 318) – (14) (29) (352) 247 1 For Life and Invest, certain corrections were made to modelled lapse rates, premium data and reinsurance recoveries. 2 For Health and Vitality, the renewal expenses assumption was updated to reflect the impact of in-period inflation being higher than assumed. 3 For Life and Invest and Health and Vitality, the economic assumptions item relates to the impact of updating the assumptions relative to the Johannesburg Stock Exchange (“JSE”) nominal and real yield risk-free curves at 31 December 2021. The Basis of Preparation section below describes an adjustment made to the nominal risk-free curve to account for an anomaly in the observed yield curve. For Life and Invest, this item also includes the impact of updating exchange rate assumptions. For VitalityLife the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest rates, offset by the net change in the interest rate hedge. 4 For Health and Vitality, the premium and fee income item relates to the impact on administration and managed care fees of in-period inflation being higher than assumed. 5 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows arising from part of the negative reserves are monetised to match other positive policy liabilities. -- 40 of 50 -- 43 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 TABLE 7: EMBEDDED VALUE OF NEW BUSINESS Six months ended % change Year ended 30 June 2021 R million 31 DECEMBER 2021 31 December 2020 Health and Vitality Present value of future profits from new business (at point of sale) 391 317 789 Cost of required capital (13) (9) (24) Present value of future profits from new business (at point of sale) after cost of required capital 378 308 23 765 New business annualised premium income1 1 634 1 416 15 3 704 Life and Invest Present value of future profits from new business (at point of sale)2 465 468 825 Cost of required capital (40) (39) (82) Present value of future profits from new business (at point of sale) after cost of required capital 425 429 (1) 743 New business annualised premium income3 1 538 1 405 9 2 947 Annualised profit margin4 3.4% 3.7% 3.0% Annualised profit margin excluding Invest business 6.8% 8.2% 5.7% VitalityHealth5 Present value of future profits from new business (at point of sale) 106 93 143 Cost of required capital (32) (30) (61) Present value of future profits from new business (at point of sale) after cost of required capital 74 63 17 82 New business annualised premium income6 752 598 26 1 263 Annualised profit margin4 1.6% 1.5% 0.9% VitalityLife7 Present value of future profits from new business (at point of sale) 100 187 396 Cost of required capital (41) (42) (95) Present value of future profits from new business (at point of sale) after cost of required capital 59 145 (59) 301 New business annualised premium income 416 448 (7) 871 Annualised profit margin4 1.9% 4.0% 4.1% -- 41 of 50 -- 44 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business written during the period but only activated after 31 December 2021. The total Health and Vitality new business annualised premium income written over the period was R3 632 million (June 2021: R6 103 million; December 2020: R2 812 million). 2 Included in the Life and Invest embedded value of new business is R35 million (June 2021: R53 million; December 2020: R29 million) in respect of investment management services provided on off balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been recognised in the value of new business. 3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. The new business annualised premium income of R1 538 million (June 2021: R2 947 million; December 2020: R1 405 million) (single premium APE: R746 million (June 2021: R1 490 million; December 2020: R699 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business annualised premium income written over the period, including automatic premium increases of R903 million (June 2021: R1 414 million; December 2020: R728 million) and servicing increases of R346 million (June 2021: R640 million; December 2020: R345 million), was R2 786 million (June 2021: R5 001 million; December 2020: R2 478 million) (single premium APE: R782 million (June 2021: R1 569 million; December 2020: R744 million)). Single premium business is included at 10% of the value of the single premium. Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances and not included as new business. Term extensions on existing contracts are not included as new business. 4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums. 5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are shown in Table 8. 6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of new business written during the period but only activated after 31 December 2021. 7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. -- 42 of 50 -- 45 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 BASIS OF PREPARATION TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS 31 DECEMBER 2021 31 December 2020 30 June 2021 Beta coefficient 0.75 0.75 0.75 Equity risk premium (%) 3.5 3.5 3.5 Risk discount rate (%) – Health and Vitality1 13.375 13.625 13.125 – Life and Invest1 13.875 14.375 13.625 – VitalityHealth 3.462 2.920 3.462 – VitalityLife 3.593 3.206 3.263 Rand / GBP exchange rate Closing 21.51 20.10 19.74 Average 20.49 21.27 20.74 Margin over Expense inflation to derive Medical inflation (%) South Africa 3.00 3.00 3.00 Expense inflation (%)2 South Africa – Health and Vitality 6.69 6.50 6.14 – Life and Invest 6.64 6.76 6.23 United Kingdom 2.50 1.50 2.50 Pre-tax investment return (%) South Africa – Cash1 9.75 10.25 9.50 – Life and Invest bonds3 11.25 11.75 11.00 – Health and Vitality bonds3 10.75 11.00 10.50 – Equity1 14.75 15.25 14.50 United Kingdom – VitalityHealth risk-free rate 0.84 0.27 0.84 – VitalityLife risk–free rate 0.97 0.58 0.64 – VitalityLife IFRS interest rate 1.82 1.49 1.80 – VitalityLife investment return 1.58 1.59 1.44 Corporation tax rate (%) South Africa 28 28 28 United Kingdom – long-term 25 19 25 VitalityHealth Assumptions – Margin (net of tax and cost of capital) (%) 12.30 14.10 12.00 – Annuity Factor 6.18 6.37 6.18 Projection term – Health and Vitality 20 years 20 years 20 years – Discovery Life – VIF 40 years 40 years 40 years – Group Life 20 years 10 years 20 years – VitalityLife No cap No cap No cap – VitalityHealth4 20 years 20 years 20 years 1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds. 2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the Bank of England inflation target. 3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown. 4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor. -- 43 of 50 -- 46 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the six months ended 31 December 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 The Discovery Limited embedded value is calculated based on a risk discount rate using the CAPM approach with specific reference to the Discovery beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta will only change if the capital structure of the Group and / or the observed beta calculated using daily returns over a long time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic performance of share prices relative to the market they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available, augmented by reinsurance and industry information. The Health and Vitality lapse assumptions were derived from the results of recent experience investigations. The VitalityHealth assumptions were derived from internal experience. VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Limited group information. Renewal expense assumptions were based on the results of the latest expense and budget information. The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of an exceptional or non-recurring nature. From 30 June 2020, the yield curves underlying the embedded value calculations were changed from the Prudential Authority yield curves to the JSE yield curves. The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publically available JSE risk-free nominal yield curve. Due to an anomaly in the JSE risk-free nominal yield curve at 31 December 2021, the yield curve used for embedded value purposes was interpolated between month 13 to 60. The real yield assumption was set relative to the publically available JSE risk-free real yield curve, adjusted to remove volatility due to the nature of the index-linked government bond market. Other economic assumptions were set relative to these two yield curves. The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the net investment return assumption. The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential Regulatory Authority yield curve. The inflation rate is consistent with the Bank of England inflation target. From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The assumptions underlying the Annuity Factor and Margin are set taking into account the current experience in the business at different durations. The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible assets. The Vitality Life Limited and the VitalityLife business on the Prudential licence required capital amount is assumed to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets. The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2. -- 44 of 50 -- 47 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 45 of 50 -- 48 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 EMBEDDED VALUE STATEMENT continued for the year ended 30 June 2021 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 SENSITIVITY TO THE EMbEDDED VALUE ASSUMPTIONS The risk discount rate uses the CAPM approach with specific reference to the Discovery beta coefficient. As beta values reflect the historic performance of share prices relative to the market they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 31 December 2021 to changes in the risk discount rate is included in the tables below. For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action such as risk premium increases where future experience is worse than the base assumptions. TABLE 9: EMBEDDED VALUE SENSITIVITY Health and Vitality Life and Invest VitalityHealth VitalityLife EMBEDDED VALUE % change R million Adjusted net worth2 Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital Base 13 797 23 844 (449) 31 342 (1 351) 9 545 (514) 9 948 (3 242) 82 920 Impact of: Risk discount rate +1% 13 797 22 518 (486) 28 435 (1 427) 9 041 (488) 9 575 (4 195) 76 770 (7) Risk discount rate – 1% 13 797 25 309 (407) 34 784 (1 259) 10 103 (543) 10 365 (1 952) 90 197 9 Lapses – 10% 13 493 24 605 (471) 34 105 (1 440) 10 891 (584) 10 780 (3 648) 87 731 6 Interest rates – 1%1 12 415 23 984 (432) 31 852 (1 316) 10 014 (543) 7 834 (3 377) 80 431 (3) Equity and property market value – 10% 13 804 23 844 (449) 30 721 (1 380) 9 545 (514) 9 948 (3 242) 82 277 (1) Equity and property return +1% 13 797 23 844 (449) 31 776 (1 355) 9 545 (514) 9 948 (3 242) 83 350 1 Renewal expenses – 10% 13 869 26 183 (416) 31 940 (1 318) 10 268 (514) 10 135 (3 193) 86 954 5 Mortality and morbidity – 5% 14 024 23 844 (449) 33 429 (1 220) 11 065 (514) 10 263 (3 210) 87 232 5 Projection term +1 year 13 797 24 133 (454) 31 434 (1 354) 9 614 (518) 9 948 (3 242) 83 358 1 1 All economic assumptions were reduced by 1%. 2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column. The following table shows the effect of using different assumptions on the embedded value of new business. TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY Health and Vitality Life and Invest VitalityHealth VitalityLife VALUE OF NEW BUSINESS % change R million Value of new business Cost of required capital Value of new business Cost of required capital Value of new business Cost of required capital Value of new business Cost of required capital Base 391 (13) 465 (40) 106 (32) 100 (41) 936 Impact of: Risk discount rate +1% 358 (14) 360 (42) 71 (30) 64 (45) 722 (23) Risk discount rate – 1% 428 (12) 588 (37) 146 (34) 141 (32) 1 188 27 Lapses – 10% 414 (14) 586 (42) 180 (35) 166 (38) 1 217 30 Interest rates – 1%1 397 (13) 469 (39) 140 (34) 3 (44) 879 (6) Equity and property return +1% 391 (13) 480 (40) 106 (32) 100 (41) 951 2 Renewal expense – 10% 449 (12) 488 (39) 149 (32) 114 (41) 1 076 15 Mortality and morbidity – 5% 391 (13) 509 (36) 196 (32) 115 (41) 1 089 16 Projection term +1 year 398 (13) 468 (40) 111 (32) 100 (41) 951 2 Acquisition costs – 10% 405 (13) 552 (40) 125 (32) 168 (41) 1 124 20 1 All economic assumptions were reduced by 1%. 48 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 49 -- 46 of 50 -- 50 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 APPENDIX A NEW bUSINESS ANNUALISED PREMIUM INCOME The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, Discovery Health Medical Scheme’s (DHMS) new business is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in respect of such services. Core new business API increased by 6% for the six months ended 31 December 2021 when compared to the same period in the prior year. R million DECEMBER 2021 December 2020 % change Discovery Health1 3 598 2 788 29 Discovery Life 1 267 1 162 9 Discovery Invest 1 519 1 316 15 Discovery Insure 597 617 (3) Discovery Vitality 34 24 42 VitalityHealth 708 638 11 VitalityLife 554 561 (1) Ping An Health (25% interest)2 1 426 1 805 (21) Other new businesses3 772 1 005 (23) Core new business API of Group 1 10 475 9 916 6 New Closed Schemes1 – 379 New business API of Group including new Closed Schemes 10 475 10 295 2 Gross revenue Vitality Group4 668 625 7 Total new business API and other new business1 11 143 10 920 2 1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings such as GAP cover and Primary Care cover. The new business API for New Closed Schemes includes contracted new business API and business in the first twelve months of on-boarding. Closed Schemes refer to those restricted to certain employers and industries. 2 New business API for PAH has been presented on a basis consistent with previous disclosures. Given the restructuring of the co-operation with Ping An Life for business written in certain regions in China as part of the overall re-alignment of PAH to focus on growing high- quality own business, going forward the core new business API measure reported for PAH sales will be redefined to reflect this re-alignment. 3 Other new businesses include the Umbrella Fund, Discovery Insure commercial and VitalityInvest. New business was impacted by the lumpy nature of Umbrella Fund sales which had strong growth in the prior period. 4 Vitality Group new business includes gross recurring and lump sum revenues earned by Vitality Group and specifically excludes revenue related to cost recoveries and rewards. Calculation of new business API New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single premium policies. It also includes both automatic premium increases and servicing increases on existing long-term insurance policies. The amounts exclude indirect taxes. The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of: ❚ The timing of inclusion of policyholders in the calculation of new business API – in the embedded value, new business is included from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new business is included when the policy has been contractually committed. ❚ Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but excluded in the embedded value API values disclosed. Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business disclosures between the embedded value and the table above. 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 25 FEbRUARY 2022 -- 47 of 50 -- 51 GROSS INFLOWS UNDER MANAGEMENT Gross inflows under management measures the total funds collected by Discovery. Gross inflows under management increased by 8% for the six months ended 31 December 2021 when compared to the same period in the prior year. R million DECEMBER 2021 December 2020 % change Discovery Health 48 200 45 876 5 Discovery Life 7 344 6 710 9 Discovery Invest 12 888 11 517 12 Discovery Insure 2 269 1 986 14 Discovery Vitality 1 140 1 132 1 VitalityHealth 5 810 5 256 11 VitalityLife 3 474 3 368 3 All other businesses 4 539 3 838 18 Gross inflows under management 85 664 79 683 8 Less: collected on behalf of third parties (47 511) (44 747) 6 Discovery Health (43 723) (41 580) 5 Discovery Invest (3 788) (3 167) 20 Gross income of Group per the segmental 38 153 34 936 9 Gross income is made up as follows: – Insurance premium revenue 29 617 26 993 10 – Fee income from administration businesses 6 187 5 701 9 – Vitality income 1 739 1 743 0 – Other income 610 499 22 Gross income of Group per the segmental information 38 153 34 936 9 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 25 FEbRUARY 2022 -- 48 of 50 -- 52 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 Transfer secretaries Computershare Investor Services Pty Limited (Registration number: 2004/003647/07) Rosebank Towers, 15 Biermann Avenue, Rosebank 2196 Private Bag X9000, Saxonwold, 2132 Sponsors and debt sponsors Rand Merchant Bank (A division of FirstRand Bank Limited) Secretary and registered office NN Mbongo, Discovery Limited (Incorporated in the Republic of South Africa) (Registration number: 1999/007789/06) Company tax reference number: 9652/003/71/7 JSE share code: DSY ISIN: ZAE000022331 JSE share code: DSBP ISIN: ZAE000158564 JSE company code: DSYI 1 Discovery Place, Sandton 2146 PO Box 786722, Sandton 2146 Tel: (011) 529 2888 Fax: (011) 539 8003 Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), HL Bosman, Dr BA Brink1, SE de Bruyn1, R Farber, WM Hlahla2, HD Kallner*, F Khanyile, NS Koopowitz*, D Macready, Dr TV Maphai, Dr A Ntsaluba*, A Pollard*, M Schreuder, B Swartzberg*, DM Viljoen* (Financial Director), SV Zilwa * Executive. 1 Retired effective 24 November 2021. 2 Appointed effective 15 August 2021. Debt officer DM Viljoen Interim financial results – supervised by DM Viljoen CA(SA) Embedded value statement – prepared by P Bolink FASSA – supervised by A Rayner FASSA, FIA 18159 • DISCOVERY UNAUDITED INTERIM RESULTS • PROOF 10 • 24 FEbRUARY 2022 -- 49 of 50 -- Discovery +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za Subsidiaries of Discovery Limited are authorised financial services providers. -- 50 of 50 --